Zealand Pharma A/S (OTCMKTS:ZLDPF) Sees Large Volume Increase – Here’s What Happened

Zealand Pharma A/S (OTCMKTS:ZLDPF) shares saw strong trading volume on Thursday . 1,614 shares traded hands during trading, an increase of 114% from the previous session’s volume of 755 shares.The stock last traded at $79.86 and had previously closed at $79.80.

Wall Street Analysts Forecast Growth

A number of research firms have commented on ZLDPF. Zacks Research raised Zealand Pharma A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 15th. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Friday, November 28th. Six research analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Strong Buy”.

Zealand Pharma A/S Price Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.10 and a current ratio of 14.10. The stock has a market capitalization of $5.59 billion, a PE ratio of 5.66 and a beta of 0.72. The company’s fifty day simple moving average is $76.67 and its two-hundred day simple moving average is $67.99.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.21. Zealand Pharma A/S had a net margin of 71.79% and a return on equity of 55.76%. The business had revenue of $7.76 million for the quarter, compared to analyst estimates of $4.54 million. As a group, sell-side analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.